Boston's HiFiBiO Raises $37.5 Million from China Investors

02:44 EDT 17 May 2018 | ChinaBio Today

HiFiBiO Therapeutics, a Boston company developing therapeutic immune modulators, closed a $37.5 million Series B financing led by two China investors, Sequoia Capital and Lyfe Capital. According to HiFiBiO, it discovers molecules based on single-B-cell screening and analysis. The company said the funding would transform HiFiBiO into a more mature biopharmaceutical company, with a stronger global presence and rich pipeline of novel antibodies for cancer and autoimmune disorders. More details....

Share this with colleagues:

Original Article: Boston's HiFiBiO Raises $37.5 Million from China Investors


More From BioPortfolio on "Boston's HiFiBiO Raises $37.5 Million from China Investors"

Quick Search


Relevant Topics

Biopharmaceuticals are medical drugs produced using biotechnology. They include proteins (including antibodies), nucleic acids (DNA, RNA or antisense oligonucleotides) and living microorganisms like virus and bacteria where the virulance of viruses and b...

An antibody is a protein produced by the body's immune system when it detects harmful substances, called antigens. Examples of antigens include microorganisms (such as bacteria, fungi, parasites, and viruses) and chemicals. Antibodies may be produc...